微创非体外循环经心室新腱索植入治疗开放手术后复发性二尖瓣反流
该国际多中心回顾性注册研究纳入92例既往二尖瓣修复后复发性反流患者,采用NeoChord技术行非体外循环微创新腱索植入。手术成功率为98.9%,5年主要复合终点达标率为81.3±6.6%,支持该技术作为再次二尖瓣手术的可选方案。
要点
- NeoChord技术手术成功率高,98.9%患者成功完成新腱索植入。
- 5年免于严重反流、再干预及死亡的主要复合终点率为81.3±6.6%。
- 高龄增加终点事件风险,较高血红蛋白水平具保护作用。
核心结论
- 微创NeoChord修复在再次二尖瓣手术中提供优异的围术期和5年结果,死亡率极低,支持其作为有价值的选择。
研究设计与样本
- 回顾性、多中心、国际注册研究,纳入2014至2025年间32个中心共92例既往二尖瓣修复后复发性二尖瓣反流患者,接受NeoChord技术治疗。
主要发现
- 新腱索修复成功91例(98.9%),1例转为开放手术。
- 出院时二尖瓣反流轻度或更轻者占93.5%。
- 1例(1.1%)于第8天死亡,报告1例危及生命的出血和1例急性心肌梗死。
- 中位住院时间5天,47.8%患者在手术室拔管。
- 5年主要复合终点达成率为81.3±6.6%(Kaplan-Meier分析)。
关键数值与推荐
- 平均年龄64.6±11.6岁,女性22例(23.9%)。
- 平均左心室射血分数57.4±8.1%,欧洲心脏手术风险评估系统评分4.3±3.2%。
- 植入腱索中位数3条,平均手术时间139±65分钟。
- 多因素分析:年龄增加与风险升高相关(风险比1.160;95%CI 1.021-1.317),较高血红蛋白水平具保护作用(风险比0.423;95%CI 0.233-0.768)。
临床怎么用
- 对于既往二尖瓣修复后复发性反流患者,尤其高风险者,可考虑微创非体外循环NeoChord新腱索植入作为再次手术选项。
局限性
- 回顾性注册研究设计,缺乏对照组,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mitral valve repair (MVr) is the standard treatment for degenerative mitral regurgitation (MR). However, MR may recur, and reoperation is associated with increased mortality and technical complexity. Microinvasive MVr using the NeoChord technique in redo setting is performed off-pump, offering clear advantages, particularly in high-risk patients. METHODS: This retrospective, multicenter, international registry included 92 patients treated with the NeoChord technique between 2014 and 2025 for recurrent MR after previous MVr across 32 centers. The primary composite end point was freedom from recurrence of severe MR, need for reintervention due to technical failure, and 30-day or cardiovascular mortality. RESULTS: Neochord repair was successful in 91 patients (98.9%); one was converted to open surgery. Mean age was 64.6 ± 11.6; 22 patients (23.9%) were female. Mean left ventricle ejection fraction was 57.4 ± 8.1%; European System for Cardiac Operative Risk Evaluation was 4.3 ± 3.2%. A median of 3 chords was implanted. Mean procedural time was 139 ± 65 minutes. At discharge, MR was mild or less in 93.5%. One patient (1.1%) died on day 8. One life-threatening bleeding and one acute myocardial infarction were reported. Median hospital length-of-stay was 5 days; 47.8% of patients were extubated in the operating room. The primary end point was achieved in 81.3 ± 6.6% of patients at 5 years (Kaplan-Meier analysis). Seven patients (8.6%) underwent re-reintervention; 3 remained with severe MR. In the multivariate analysis, older age was associated with an increased risk (hazard ratio, 1.160; 95% CI, 1.021-1.317), whereas greater hemoglobin levels were protective (hazard ratio, 0.423; 95% CI, 0.233-0.768). CONCLUSIONS: Microinvasive NeoChord repair provides excellent procedural and 5-year outcomes with very low mortality, supporting its role as a valuable option for reoperative mitral valve surgery.
引用
- Salizzoni S, Yadav R, Sardari Nia P, et al. Microinvasive, off-pump, transventricular neochordae implantation in recurrent mitral valve regurgitation after open heart surgical repair. J Thorac Cardiovasc Surg. 2026. PMID: 41763387. doi:10.1016/j.jtcvs.2026.01.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。